Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Polarean Imaging: shareholders approve delisting from AIM

Polarean Imaging shareholders voted 80.71% in favour of revoking the admission to trading on AIM; 19.29% voted against. Trading on AIM will be suspended on 23 December 2025, with the last day of trading on 22 December, and the conversion into a private company is expected to be completed by 12 January 2026. Polarean is establishing a "Matched Bargain Facility" via J P Jenkins of Prosper Capital to enable trading in the unlisted shares for at least twelve months; shareholders can continue to hold shares uncertificated through CREST. The company currently has 1,207,032,781 ordinary shares issued. » More on de.investing.com
Polarean: XENOVIEW chest coil compatible with Philips 3.0T MRI systems

Polarean has successfully completed validation of its FDA‑cleared XENOVIEW 3T chest coil for compatibility with Philips MRI platforms, including the MR 7700 and Ingenia Elition X. The validation enables integration into Philips systems from early 2026 and expands the availability of non‑invasive, quantitative lung function assessments for Philips MRI users. The result supports Polarean’s position to more broadly deploy its xenon MRI technology in clinical practice. » More on de.investing.com
Polarean Imaging delivers xenon MRI system to US health agency NIH

Polarean Imaging has received an order from the NIH Clinical Center in Bethesda for a xenon MRI system for lung imaging. The system enables high-performance polarization of xenon to investigate innovative MRI techniques for better characterization of lung diseases. Polarean will work with Dr. Campbell-Washburns team at the NIH to jointly research respiratory diseases. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2023, POLAREAN IMAG.LS-,00037 has already paid €0.89 in dividends. The last payout was in July 2023.

Financials

In the last quarter, POLAREAN IMAG.LS-,00037 had revenue of €534.36k and net profit of -€4.55m

(EUR)	June 2025	YoY
Revenue	534.36k	-
Gross profit	81.26k	-
Net profit	-4.55m	-
EBITDA	-4.34m	-

Fundamentals

Metric	Value
Market capitalization	€7.23m
Number of shares	1.21bn
52-week high/low	€0.00608 - €0.000907
Dividends	No
Beta	0.09
P/E ratio	-0.12
PEG ratio	0.00
P/B ratio	0.07
P/S ratio	0.53

Company profile

Polarean Imaging plc operates as a medical drug-device combination company serving the medical imaging market in the United States, Canada, Germany, and the United Kingdom. The company engages in the development and commercialization of gas polarizer devices and ancillary instruments. It develops equipment that enables existing magnetic resonance imaging (MRI) systems to achieve a level of pulmonary functional imaging and specializes in the use of hyperpolarized xenon gas (129Xe) as an imaging agent to visualize ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream, and in the pulmonary vasculature; and a novel diagnostic approach. The company is also involved in the development and manufacture of MRI radiofrequency coils, which are required components for imaging 129Xe in the MRI system. Polarean Imaging plc was incorporated in 2016 and is based in Durham, North Carolina.